Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16410 entries
Sorted by: Best Match Show Resources per page
Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment.

OncoTargets and therapy

Rachmut IH, Samuels N, Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J.
PMID: 23637542
Onco Targets Ther. 2013 Apr 24;6:437-45. doi: 10.2147/OTT.S42038. Print 2013.

OBJECTIVE: To examine the effects of LSC101, a botanical compound, on adaptive and innate immunity.MATERIALS AND METHODS: LCS101 preparations were tested for batch-to-batch consistency using high-performance liquid chromatography. T-cell activation was quantified in murine spleen cells using 3H-thymidine incorporation,...

Cite
Rachmut IH, Samuels N, Melnick SJ, et al. Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. Onco Targets Ther. 2013;6:437-45doi: 10.2147/OTT.S42038.
Rachmut, I. H., Samuels, N., Melnick, S. J., Ramachandran, C., Sharabi, Y., Pavlovsky, A., Maimon, Y., & Shoham, J. (2013). Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. OncoTargets and therapy, 6437-45. https://doi.org/10.2147/OTT.S42038
Rachmut, Itzchak H, et al. "Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment." OncoTargets and therapy vol. 6 (2013): 437-45. doi: https://doi.org/10.2147/OTT.S42038
Rachmut IH, Samuels N, Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J. Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. Onco Targets Ther. 2013 Apr 24;6:437-45. doi: 10.2147/OTT.S42038. Print 2013. PMID: 23637542; PMCID: PMC3639221.
Copy Download .nbib Format: NLM
Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K.
PMID: 24124381
Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that...

Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
Oncogene mutational profile in nasopharyngeal carcinoma.

OncoTargets and therapy

Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY.
PMID: 24672248
Onco Targets Ther. 2014 Mar 20;7:457-67. doi: 10.2147/OTT.S58791. eCollection 2014.

Nasopharyngeal carcinoma (NPC) is a common tumor in Southern China, but the oncogene mutational status of NPC patients has not been clarified. Using time-of-flight mass spectrometry, 238 mutation hotspots in 19 oncogenes were examined in 123 NPC patients. The...

Cite
Zhang ZC, Fu S, Wang F, et al. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014;7:457-67doi: 10.2147/OTT.S58791.
Zhang, Z. C., Fu, S., Wang, F., Wang, H. Y., Zeng, Y. X., & Shao, J. Y. (2014). Oncogene mutational profile in nasopharyngeal carcinoma. OncoTargets and therapy, 7457-67. https://doi.org/10.2147/OTT.S58791
Zhang, Zi-Chen, et al. "Oncogene mutational profile in nasopharyngeal carcinoma." OncoTargets and therapy vol. 7 (2014): 457-67. doi: https://doi.org/10.2147/OTT.S58791
Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014 Mar 20;7:457-67. doi: 10.2147/OTT.S58791. eCollection 2014. PMID: 24672248; PMCID: PMC3964172.
Copy Download .nbib Format: NLM
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib.

OncoTargets and therapy

Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L.
PMID: 23251095
Onco Targets Ther. 2012;5:439-47. doi: 10.2147/OTT.S37289. Epub 2012 Dec 12.

BACKGROUND: Previous studies have reported that epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the...

Cite
Xu F, Wu J, Xue C, et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012;5:439-47doi: 10.2147/OTT.S37289.
Xu, F., Wu, J., Xue, C., Zhao, Y., Jiang, W., Lin, L., Wu, X., Lu, Y., Bai, H., Xu, J., Zhu, G., & Zhang, L. (2012). Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and therapy, 5439-47. https://doi.org/10.2147/OTT.S37289
Xu, Fei, et al. "Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib." OncoTargets and therapy vol. 5 (2012): 439-47. doi: https://doi.org/10.2147/OTT.S37289
Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012;5:439-47. doi: 10.2147/OTT.S37289. Epub 2012 Dec 12. PMID: 23251095; PMCID: PMC3525047.
Copy Download .nbib Format: NLM
Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition.

OncoTargets and therapy

Ma YY, Yu S, He XJ, Xu Y, Wu F, Xia YJ, Guo K, Wang HJ, Ye ZY, Zhang W, Tao HQ.
PMID: 24833907
Onco Targets Ther. 2014 May 02;7:637-43. doi: 10.2147/OTT.S60458. eCollection 2014.

The aim of this study was to discuss the role of c-KIT mutation in the pathogenesis of gastrointestinal stromal tumors (GISTs) and analyze its correlation with proliferation and apoptosis. c-KIT and PDGFRA genotypes were examined by deoxyribonucleic acid sequencing....

Cite
Ma YY, Yu S, He XJ, et al. Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. Onco Targets Ther. 2014;7:637-43doi: 10.2147/OTT.S60458.
Ma, Y. Y., Yu, S., He, X. J., Xu, Y., Wu, F., Xia, Y. J., Guo, K., Wang, H. J., Ye, Z. Y., Zhang, W., & Tao, H. Q. (2014). Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. OncoTargets and therapy, 7637-43. https://doi.org/10.2147/OTT.S60458
Ma, Ying-Yu, et al. "Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition." OncoTargets and therapy vol. 7 (2014): 637-43. doi: https://doi.org/10.2147/OTT.S60458
Ma YY, Yu S, He XJ, Xu Y, Wu F, Xia YJ, Guo K, Wang HJ, Ye ZY, Zhang W, Tao HQ. Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. Onco Targets Ther. 2014 May 02;7:637-43. doi: 10.2147/OTT.S60458. eCollection 2014. PMID: 24833907; PMCID: PMC4014364.
Copy Download .nbib Format: NLM
Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer.

OncoTargets and therapy

Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, Lin X, Magaye R, Zhao J.
PMID: 24204158
Onco Targets Ther. 2013 Oct 16;6:1437-44. doi: 10.2147/OTT.S51997. eCollection 2013.

The expression and clinical significance of insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin-like growth factor binding protein 7 (IGFBP-7) were investigated in serum and lung cancer tissues from 57 patients with non-small...

Cite
Wang Z, Wang Z, Liang Z, et al. Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther. 2013;6:1437-44doi: 10.2147/OTT.S51997.
Wang, Z., Wang, Z., Liang, Z., Liu, J., Shi, W., Bai, P., Lin, X., Magaye, R., & Zhao, J. (2013). Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. OncoTargets and therapy, 61437-44. https://doi.org/10.2147/OTT.S51997
Wang, Zhigang, et al. "Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer." OncoTargets and therapy vol. 6 (2013): 1437-44. doi: https://doi.org/10.2147/OTT.S51997
Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, Lin X, Magaye R, Zhao J. Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther. 2013 Oct 16;6:1437-44. doi: 10.2147/OTT.S51997. eCollection 2013. PMID: 24204158; PMCID: PMC3804563.
Copy Download .nbib Format: NLM
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.

OncoTargets and therapy

Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L.
PMID: 24204163
Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013.

BACKGROUND: Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are widely used for EGFR mutated non-small-cell lung cancer (NSCLC) patients, tumor sample availability and heterogeneity of the tumor remain challenging for physicians' selection of these patients. Here, we...

Cite
Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013;6:1481-91doi: 10.2147/OTT.S51887.
Wu, X., Liang, W., Hou, X., Lin, Z., Zhao, H., Huang, Y., Fang, W., Zhao, Y., Wu, J., Yang, Y., Xue, C., Hu, Z., Zhang, J., Zhang, J., Ma, Y., Zhou, T., Qin, T., & Zhang, L. (2013). Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and therapy, 61481-91. https://doi.org/10.2147/OTT.S51887
Wu, Xuan, et al. "Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC." OncoTargets and therapy vol. 6 (2013): 1481-91. doi: https://doi.org/10.2147/OTT.S51887
Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013. PMID: 24204163; PMCID: PMC3818102.
Copy Download .nbib Format: NLM
Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

OncoTargets and therapy

Chen D, Cheng J, Yang K, Ma Y, Yang F.
PMID: 24187501
Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013.

BACKGROUND: Chronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil (5-Fu) can significantly improve efficacy and...

Cite
Chen D, Cheng J, Yang K, et al. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013;6:1507-14doi: 10.2147/OTT.S53098.
Chen, D., Cheng, J., Yang, K., Ma, Y., & Yang, F. (2013). Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. OncoTargets and therapy, 61507-14. https://doi.org/10.2147/OTT.S53098
Chen, Dan, et al. "Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma." OncoTargets and therapy vol. 6 (2013): 1507-14. doi: https://doi.org/10.2147/OTT.S53098
Chen D, Cheng J, Yang K, Ma Y, Yang F. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013 Oct 24;6:1507-14. doi: 10.2147/OTT.S53098. eCollection 2013. PMID: 24187501; PMCID: PMC3810446.
Copy Download .nbib Format: NLM
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.

Oncotarget

Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS.
PMID: 28938542
Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29.

Multiple myeloma (MM) remains as an incurable disease, despite recent substantial improvements in treatment. Therefore, development of novel biomarkers for risk stratification and new therapeutic targets are imperative. One of the emerging treatments for MM is the immune checkpoint...

Cite
Roh J, Jeon Y, Lee AN, et al. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget. 2017;8(35):58122-58132doi: 10.18632/oncotarget.19468.
Roh, J., Jeon, Y., Lee, A. N., Lee, S. M., Kim, Y., Sung, C. O., Park, C. J., Hong, J. Y., Yoon, D. H., Suh, C., Huh, J., Choi, I., & Park, C. S. (2017). The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget, 8(35), 58122-58132. https://doi.org/10.18632/oncotarget.19468
Roh, Jin, et al. "The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma." Oncotarget vol. 8,35 (2017): 58122-58132. doi: https://doi.org/10.18632/oncotarget.19468
Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29. PMID: 28938542; PMCID: PMC5601638.
Copy Download .nbib Format: NLM
PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition.

Oncotarget

Leng S, Yang M, Zhao Y, Zhao J, Zeng Z, Yang Y, Yuan J, Lv B, Jun F, Wang B.
PMID: 28938547
Oncotarget. 2017 Mar 22;8(35):58184-58198. doi: 10.18632/oncotarget.16436. eCollection 2017 Aug 29.

Hepatocellular carcinoma (HCC) is one of the most lethal tumors worldwide, which is mainly due to the high recurrence and metastasis rate after hepatectomy. In this study, we found that PTIP expression was dramatically upregulated in human HCC tissues...

Cite
Leng S, Yang M, Zhao Y, et al. PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition. Oncotarget. 2017;8(35):58184-58198doi: 10.18632/oncotarget.16436.
Leng, S., Yang, M., Zhao, Y., Zhao, J., Zeng, Z., Yang, Y., Yuan, J., Lv, B., Jun, F., & Wang, B. (2017). PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition. Oncotarget, 8(35), 58184-58198. https://doi.org/10.18632/oncotarget.16436
Leng, Shusheng, et al. "PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition." Oncotarget vol. 8,35 (2017): 58184-58198. doi: https://doi.org/10.18632/oncotarget.16436
Leng S, Yang M, Zhao Y, Zhao J, Zeng Z, Yang Y, Yuan J, Lv B, Jun F, Wang B. PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition. Oncotarget. 2017 Mar 22;8(35):58184-58198. doi: 10.18632/oncotarget.16436. eCollection 2017 Aug 29. PMID: 28938547; PMCID: PMC5601643.
Copy Download .nbib Format: NLM
Prognostic value of DNA repair genes based on stratification of glioblastomas.

Oncotarget

Kun S, Duan Q, Liu G, Lu JM.
PMID: 28938550
Oncotarget. 2017 Apr 27;8(35):58222-58230. doi: 10.18632/oncotarget.17452. eCollection 2017 Aug 29.

Abnormal expression of DNA repair genes is frequently associated with cancerogenesis of many tumors, however, the role DNA repair genes play in the progression of glioblastoma remains unclear. In this study, taking advantage of large scale of RNA-seq data,...

Cite
Kun S, Duan Q, Liu G, et al. Prognostic value of DNA repair genes based on stratification of glioblastomas. Oncotarget. 2017;8(35):58222-58230doi: 10.18632/oncotarget.17452.
Kun, S., Duan, Q., Liu, G., & Lu, J. M. (2017). Prognostic value of DNA repair genes based on stratification of glioblastomas. Oncotarget, 8(35), 58222-58230. https://doi.org/10.18632/oncotarget.17452
Kun, Sun, et al. "Prognostic value of DNA repair genes based on stratification of glioblastomas." Oncotarget vol. 8,35 (2017): 58222-58230. doi: https://doi.org/10.18632/oncotarget.17452
Kun S, Duan Q, Liu G, Lu JM. Prognostic value of DNA repair genes based on stratification of glioblastomas. Oncotarget. 2017 Apr 27;8(35):58222-58230. doi: 10.18632/oncotarget.17452. eCollection 2017 Aug 29. PMID: 28938550; PMCID: PMC5601646.
Copy Download .nbib Format: NLM
LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells.

Oncotarget

Shi X, Zhang H, Wang M, Xu X, Zhao Y, He R, Zhang M, Zhou M, Li X, Peng F, Shi C, Shen M, Wang X, Guo X, Qin R.
PMID: 28938565
Oncotarget. 2017 Apr 06;8(35):58394-58404. doi: 10.18632/oncotarget.16880. eCollection 2017 Aug 29.

We investigated the role of actin filament associated protein 1 antisense RNA1 (AFAP1-AS1) lncRNA in promoting cholangiocarcinoma (CCA). qRT-PCR analysis of patient samples showed that AFAP1-AS1 expression was higher in CCA tumors than matched adjacent non-tumor tissue. AFAP1-AS1 levels...

Cite
Shi X, Zhang H, Wang M, et al. LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. Oncotarget. 2017;8(35):58394-58404doi: 10.18632/oncotarget.16880.
Shi, X., Zhang, H., Wang, M., Xu, X., Zhao, Y., He, R., Zhang, M., Zhou, M., Li, X., Peng, F., Shi, C., Shen, M., Wang, X., Guo, X., & Qin, R. (2017). LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. Oncotarget, 8(35), 58394-58404. https://doi.org/10.18632/oncotarget.16880
Shi, Xiuhui, et al. "LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells." Oncotarget vol. 8,35 (2017): 58394-58404. doi: https://doi.org/10.18632/oncotarget.16880
Shi X, Zhang H, Wang M, Xu X, Zhao Y, He R, Zhang M, Zhou M, Li X, Peng F, Shi C, Shen M, Wang X, Guo X, Qin R. LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. Oncotarget. 2017 Apr 06;8(35):58394-58404. doi: 10.18632/oncotarget.16880. eCollection 2017 Aug 29. PMID: 28938565; PMCID: PMC5601661.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16410 entries